Health and Global Policy Institution (HGPI) conducted the “First forum: Technical Issues-Analysis and Appraisal Issues Identified through the Trial Introduction of Cost-Effectiveness Assessment” on 19 July 2018.

In order to widely contribute to society and to promote the public consensus regarding the field of Health Technology Assessment (HTA) policy, HGPI organized a series of forums bringing together multi-stakeholders from academia, government, industry and civil society. Discussions performed to facilitate the rebalancing of healthcare system innovation and sustainability.

HGPI conducted a preparatory meeting entitled “ Rebalancing Healthcare Systems: Innovation and Sustainability Series – Issues Identified from the Trial Introduction of Cost-Effectiveness Assessment” in May 2018 as a kick-off of the main Forum Series. To identify the priority issues to be tackled during the Forum Series that is taking place in 2018. Based on the issue topics raised in the preparatory meeting, a roundtable discussion took place discussing the technical issues of Cost-Effective Assessment at this forum.

The schedules of the future forums within this series will be held as follows;

• Second Forum (September 2018): Issues for Institutionalization
  – Introduction of Cost-Effectiveness Assessment, Its Impacts and Compatibility with Other Systems-
• Third Forum (October 2018): Public Understanding
  -Raising Public Awareness on the Meaning and Benefits of Cost-Effectiveness Assessment and Relevant Discussions

________________________________________
Organizer: Health and Global Policy Institute (HGPI)
Participants: Policymakers, relevant ministry officials, academic and corporate stakeholders, etc.

Opening (Explanatory introduction)

• Joji Sugawara (Associate, HGPI)

Roundtable discussion on Technical Issues -Analysis and Appraisal Issues Identified through the Trial Introduction of Cost-Effectiveness Assessment-

Roundtable speakers (titles omitted, in Japanese syllabary order):

• Manabu Akazawa (Professor, Department of Public Health and Epidemiology, Meiji Pharmaceutical University)
• Shunya Ikeda (Professor, Graduate School of Medicine/Public Health, International University of Health and Welfare)
• Mamoru Ichikawa (Principal Program Director, Production Center I Science Programs Division, Program Production Department, Japan Broadcasting Corporation (NHK))
• Satoshi Imamura (Vice-President, Japan Medical Association)
• Yoshie Onishi (Director, Japan Operations, Creativ-Ceutical K.K.)
• Kosuke Kato (Managing Director, Edwards Lifesciences Limited)
• Keiji Kono (Senior Vice President, Global Health Policy, External Affairs, Chugai Pharmaceutical Co., Ltd.)
• Hidehito Kotani (President, PHC Holdings Corporation)
• Shigekazu Komoto (Planning Officer, Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW))
• Naokazu Saito (Chief, Policy Intelligence Division, Integrated Market Access Department, Janssen Pharmaceutical K.K.)
• Naomi Sakurai (President, Cancer Solutions Co., Ltd.)
• Kojiro Shimozuma (Professor, Department of Biomedical Sciences, Graduate School of Life Sciences, Ritsumeikan University)
• Tomoyuki Takura (Project Professor, Department of Healthcare Economics and Health Policy, Graduate School of Medicine and Faculty of Medicine, University of Tokyo)
• Toshio Nagase (Director, Government Affairs, Gilead Science K.K.)
• Hiroshi Nakamura (Professor, Graduate School of Business Administration, Keio University)
• Takashi Fukuda (Director, Department of Health and Welfare Service, National Institution of Public health)
• Yoshiyuki Majima (President, Pancreatic Cancer Action Network Japan)

Moderators:

• Ryoji Noritake (President, HGPI)

MC

• Yuiko Kondo (Senior Associate, HGPI)